The Emerging Story of FLASH Radiotherapy (FOR INVESTIGATIONAL USE ONLY)

FOR INVESTIGATIONAL USE ONLY Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA. The FLASH Effect: Establishing a Path to Human Clinical Trials (Part 1 of 4) Part 2:    • The FLASH Effect: Establishing a Path to H...   Part 3:    • Clinical perspectives for FLASH Therapy (F...   Part 4:    • Questions and Answers–The FLASH Effect: Es...   PRESENTED BY: Marie-Catherine Vozenin, PhD, HDR Chief of Radiation Oncology Research Lab Lausanne University Hospital | CHUV Marie-Catherine Vozenin is an Associate Professor of Radiation Oncology and the Chief of Radiation Oncology Research Lab at Lausanne University Hospital (CHUV) since 2013. She is also currently an Adjunct Professor at the University of California in Irvine. Dr. Vozenin's research group has pioneered developing innovative approaches to increase the therapeutic ratio of radiation therapy. Her recent path-breaking work on FLASH-RT has shown excellent tumor kill efficacy associated with protective effects on the normal tissue. Marie-Catherine completed her Ph.D. in oncology and radiobiology at the University of Paris-SUD. She has published over 100 publications in peer-reviewed journals with over 20 dedicated to the exploration of FLASH-RT.